Bachem Holding AG
SIX:BANB

Watchlist Manager
Bachem Holding AG Logo
Bachem Holding AG
SIX:BANB
Watchlist
Price: 75.15 CHF 7.51% Market Closed
Market Cap: CHf5.6B

Gross Margin

31.2%
Current
Improving
by 0.4%
vs 3-y average of 30.8%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
31.2%
=
Gross Profit
CHf211.7m
/
Revenue
CHf677.9m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
31.2%
=
Gross Profit
CHf211.7m
/
Revenue
CHf677.9m

Peer Comparison

Country Company Market Cap Gross
Margin
CH
Bachem Holding AG
SIX:BANB
5.6B CHF
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
237.8B USD
Loading...
US
Danaher Corp
NYSE:DHR
166.8B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
83.6T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.4B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.1B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
277.8B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.3B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.9B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.2B EUR
Loading...

Market Distribution

Lower than 77% of companies in Switzerland
Percentile
23rd
Based on 957 companies
23rd percentile
31.2%
Low
-13 700% — 34.9%
Typical Range
34.9% — 65.3%
High
65.3% — 137.7%
Distribution Statistics
Switzerland
Min -13 700%
30th Percentile 34.9%
Median 49.4%
70th Percentile 65.3%
Max 137.7%

Bachem Holding AG
Glance View

In the heart of the Swiss pharmaceutical industry, Bachem Holding AG has carved out a distinct niche as a leading player in the peptide manufacturing landscape. Founded by Peter Grogg in 1971, Bachem has grown from a modest laboratory venture into a global powerhouse with an exceptional focus on peptides and oligonucleotide development. These biomolecules, small chains of amino acids, and nucleotides respectively, play crucial roles in modern therapeutics, acting as key components in drug design for treating various ailments. From its headquarters in Bubendorf, Switzerland, Bachem leverages cutting-edge technologies to enhance the purity and scalability of peptide production, meeting the demand from pharmaceutical and biotechnology companies worldwide. By establishing a robust supply chain and maintaining high standards of quality control, the company ensures the reliability and success of its partnerships. At the core of Bachem's business model is the offering of customized products and services tailored to client-specific needs, ranging from research-grade to commercial-scale production. The company generates revenue through long-term contracts and ongoing relationships with key players in the global pharmaceutical industry. As drug discovery advances, Bachem’s role in providing essential active pharmaceutical ingredients (APIs) becomes increasingly central, facilitating the development of novel therapies. The company also invests heavily in research and development to continuously refine its manufacturing processes and expand its service portfolio. By marrying scientific expertise with strategic foresight, Bachem not only anchors itself in the present pharmaceutical landscape but also positions itself for future growth in the biotechnology sector.

BANB Intrinsic Value
HIDDEN
Show
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
31.2%
=
Gross Profit
CHf211.7m
/
Revenue
CHf677.9m
What is Bachem Holding AG's current Gross Margin?

The current Gross Margin for Bachem Holding AG is 31.2%, which is above its 3-year median of 30.8%.

How has Gross Margin changed over time?

Over the last 3 years, Bachem Holding AG’s Gross Margin has decreased from 31.6% to 31.2%. During this period, it reached a low of 29.6% on Jun 30, 2023 and a high of 32.2% on Dec 31, 2022.

Back to Top